Tumor marker levels elevate false-positively in postsurgical Breast Cancer patients with high sgpt levels or with receiving oral 5-FU or its derivatives

Breast Cancer ◽  
1999 ◽  
Vol 6 (3) ◽  
pp. 181-186
Author(s):  
Kazuhiko Asanuma ◽  
Yoshihisa Hama ◽  
Shinya Kobayashi ◽  
Kiyoshi Shingu ◽  
Shiro Yokoyama ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Breast Cancer Patients

Tumor Marker–Guided PET in Breast Cancer Patients—A Recipe for a Perfect Wedding

2012 ◽  
Vol 37 (5) ◽  
pp. 467-474 ◽  
Author(s):  
Laura Evangelista ◽  
Anna Rita Cervino ◽  
Cristina Ghiotto ◽  
Adil Al-Nahhas ◽  
Domenico Rubello ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Breast Cancer Patients

Prelimenary results of a phase I/II of a combination of cetuximab and taxane for triple negative breast cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e12018-e12018
Author(s):  
H. Nechushtan ◽  
H. Steinberg ◽  
T. Peretz
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Patient Characteristics ◽  
Chemotherapeutic Agents ◽  
Breast Cancer Patients ◽  
Egfr Expression ◽  
Nail Disease

e12018 Background: The triple negative subtype of breast cancer is currently only treated with chemotherapeutic agents. It has been demonstrated that over 50% of this kind of tumors express EGFR (HER-1). Cetuximab is a humanized antiEGFR IgG1 antibody. In colon cancer there are also high percentage of EGFR expression and addition of Cetuximab to chemotherapy results in renewed sensitivity to treatments. We therefore hypothesized that in a similar manner addition of Cetuximab to taxanes which are among the most potent anti breast cancer drugs will result in increased effectiveness in this subset of breast cancer patients. Methods: From January 2007 to January 2009, we treated 12 breast cancer patients with either paclitaxel 80 mg/m2, (10 patients) or docetaxel (30 mg mg/m2) (2 patients), with cetuximab weekly. Patients had a pathology sample of breast cancer with triple negative components, metastatic disease and up to two prior chemotherapy lines in the metastatic settings. Results: Patient characteristics (median): age 60 (31–69) years, prior taxane therapy 9/12 pts. Toxicity: Dermatologic grade 2 9/12 grade 3 3/12, nail disease grade 2 10/12 evaluable patients. One patient developed severe swallowing difficulties after 19 month of therapy which may or may not be linked to the treatment. Response is evaluable for 11/12 patients. Response which includes clinical response, tumor marker decrease, and a metastasis size decrease was noted in 9/11 patients. Including tumor marker normalization and nearly a roentgoenolgic CR in a young patient previously treated with several chemeotherapietic lines. Three patients developed brain metastasis during treatments. Molecular pathology is now performed. We continue accrual. Conclusions: Administration of taxane-cetuximab weekly therapy for triple negative breast cancer patients is possible. Toxicity is the cumulated expected toxicity of each of the agents — special care should be taken for nail disease which occurred in most of the patients. Some impressive clinical responses were obtained even in taxane pretreated patients. [Table: see text]

Longitudinal follow-up of breast cancer patients with the tumor markers CA 549 and CA 15.3

1995 ◽  
Vol 10 (1) ◽  
pp. 30-34 ◽  
Author(s):  
L. Vankrieken ◽  
F. Heureux ◽  
J. Longueville ◽  
R. De Hertogh
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Clinical Situation ◽  
Breast Cancer Patients ◽  
Significant Information ◽  
Ca 15.3 ◽  
Cutoff Levels

In order to verify the efficiency of the tumor markers CA 15.3 and CA 549 in the follow-up of breast cancer patients, it was necessary first to check the cutoff levels of each tumor marker in women with an increased age-related risk, but with no evidence of disease. From 132 serum samples in this age group, we confirmed the CA 549 cutoff level of 12.1 U/ml. However, the cutoff of CA 15.3 was 34 U/ml, which is higher than previously reported in the literature. Fifty-two breast cancer patients with or without metastases at the time of entry into the study were followed for 2 to 3 years with both tumor markers. The sensitivity, specificity and the test efficiency for the presence of metastases were analyzed with each tumor marker. Taking into account the different cutoff levels, we concluded that both tumor markers can be used independently to follow the clinical situation of patients. In several cases an increase in both tumor markers was observed before a clinical diagnosis of metastases could be made. Combination of these two tumor markers gave no more significant information about the patient's clinical situation than each tumor marker alone.

CSLEX (Sialyl Lewis X) is a Useful Tumor Marker for Monitoring of Breast Cancer Patients

2010 ◽  
Vol 41 (3) ◽  
pp. 394-399 ◽  
Author(s):  
Tomoyuki Fujita ◽  
Koichi Murayama ◽  
Toru Hanamura ◽  
Toshihiro Okada ◽  
Tokiko Ito ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Sialyl Lewis X ◽  
Breast Cancer Patients ◽  
Lewis X ◽  
Sialyl Lewis
Sign in / Sign up

Export Citation Format

Share Document